We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Biogen Inc | NASDAQ:BIIB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 8.44 | 3.72% | 235.32 | 234.58 | 236.00 | 236.90 | 228.66 | 228.98 | 1,792,636 | 00:38:42 |
From May 2019 to May 2024
By Colin Kellaher
Biogen Inc. (BIIB) on Tuesday said a Phase 2 study of its BIIB059 antibody in patients with the autoimmune disease lupus met its primary endpoints, showing statistically significant reduction of disease activity compared to placebo.
The Cambridge, Mass., biopharmaceutical company said the two-part study evaluated BIIB059 in individuals with active cutaneous lupus erythematosus, including chronic and subacute subtypes, with or without systemic manifestations, and in individuals with systemic lupus erythematosus with active joint and skin manifestations.
Biogen said the safety and tolerability profile of BIIB059 supports its continued development, adding that the study results support the company's goal of building a multi-franchise portfolio.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 03, 2019 08:00 ET (13:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Biogen Chart |
1 Month Biogen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
